Mohamed L. Salem

Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.

S. Mehrotra, E. Garrett-Mayer, J. Wrangle, 2018, Cancer research.

Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.

C. Paulos, M. Rubinstein, D. Cole, 2012, Journal of the American College of Surgeons.